Interim Results
Group |
Number |
Percent* |
All patients |
488 |
|
Enrolled to trial |
348 |
71.3% |
Treatment ended |
240 |
69.0% |
Full course of treatment |
134 |
55.8% |
6-month follow-up |
78 |
58.2% |
Sustained viral response |
67 |
85.9% |
* Of the preceding row
Previous Slide Contents Next Slide